ClinPhone and Cytel - A New Partnership Delivering Complete Solutions for Adaptive Clinical Trials
News Jul 03, 2008
ClinPhone and Cytel Inc. have announced a unique partnership that unites Cytel's validated adaptive trial statistical and computational expertise with ClinPhone's robust suite of clinical technologies and operational know-how.
This new partnership offers sponsors the combined expertise of the two organizations in successful design, planning and implementation of adaptive and other complex study designs.
ClinPhone-Cytel adaptive trial solutions are tailored to the requirements and objectives of each individual clinical development program. This integrated service provides all the essential components for adaptive trial planning and implementation, including study design consulting, trial simulations, supplies planning and management, clinical data collection, randomization, trial supply management, data analysis and reporting.
Adaptive Clinical Trials (ACTs) refer to clinical studies that use accumulating response data to optimize pre-determined aspects of the study design without undermining the validity and integrity of the trial.
By making mid-course adjustments to the trial, adaptive trials increase the ability to answer the study's key research objectives, and improve the likelihood of a successful outcome. ClinPhone-Cytel solutions combine the innovative statistical techniques and trial technology advances that make designing and conducting adaptive trials practical for sponsor organizations of all sizes.
Irving Dark, Cytel's Vice President of Clinical Research Services explains, "The ClinPhone-Cytel collaboration provides sponsors with the full-service offering needed for successful Adaptive Clinical Trials. This partnership underscores our commitment to be the leader in innovative trial design and implementation services."
Dr. Bill Byrom, Vice President, Product Strategy and Marketing of ClinPhone comments, "Technology plays a central role in delivering these types of studies, and Cytel and ClinPhone together are leading the way in offering integrated services that provide a comprehensive solution for the sponsor wishing to benefit from the power of adaptive trials."
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019